Intervju med vd Andreas Bhagwani gällande den fullt garanterade företrädesemissionen av units om ca 99,4 MSEK.

August 29, 2024
Featured news, News, Presentationer, Presentations

Den 29 augusti offentliggjorde Nanologica att bolaget avser att genomföra en fullt garanterad företrädesemission av units om ca 99,4 MSEK. I intervjun berättar vd Andreas Bhagwani mer om emissionen och bakgrunden till den.

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Intervju med vd Andreas Bhagwani gällande den fullt garanterade företrädesemissionen av units om ca 99,4 MSEK.

Share this: